Amlodipine/rosuvastatin - Alvogen Korea

Drug Profile

Amlodipine/rosuvastatin - Alvogen Korea

Alternative Names: C1 R212+C2 R212; C1-R212/C2-R212; DP-R212

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Alvogen Korea
  • Class Antihypertensives; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hyperlipidaemia; Hypertension

Most Recent Events

  • 11 Nov 2016 Chemical structure information added
  • 03 Nov 2016 Alvogen Korea plans a phase III trial for Hypertension and Hypercholesterolaemia in South Korea (PO) (NCT02955368)
  • 12 Jun 2016 Alvogen Korea plans a phase I pharmacokinetic trial in healthy volunteers in South Korea (NCT02814500)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top